IMVT Immunovant, Inc.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Graves’ ophthalmopathy (GO). We submitted an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in November 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases.

$3.98  +0.08 (1.92%)
As of 07/01/2022 15:59:55 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2019
Outstanding shares:  116,505,412
Average volume:  327,298
Market cap:   $454,371,107
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJRFSB7

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.91
PS ratio:   0.00
Return on equity:   -27.26%
Net income %:   0.00%